Business Wire

Hakan Koç and Pyrros Koussios Complete Acquisition of eSIM and Compliance Technology Leader Truphone

24.1.2023 18:23:00 EET | Business Wire | Press release

Share

German businessman and tech entrepreneur Hakan Koç and former telecoms executive and private equity investor Pyrros Koussios (the “Investors”), today announce that they have completed, with immediate effect, their acquisition of Truphone, the first global mobile operator.

The Investors are buying the assets and subsidiaries of Truphone Limited, following the completion today of the company’s restructuring and the recent receipt of National Security and Investment Clearance from Rt Hon. Grant Shapps MP, the Secretary of State for Business, Energy and Industrial Strategy (BEIS) as well as a license from the Office of Financial Sanctions Implementation (OFSI) at HM Treasury.

The assets of the Truphone business have been acquired by TP Global Operations Ltd., a newly incorporated vehicle that is 100% owned by the Investors. The Investors intend to immediately provide additional funding to support the ongoing business and its future development, with a particular focus on its leading product offerings in the areas of:

  • The growing market of compliance solutions for recording mobile communications and messages for regulated financial institutions. This is a domain where Truphone already offers some of the most innovative solutions accepted worldwide by regulators, serving the increasing demands for compliance technologies that financial institutions like banks and asset managers are facing
  • Its leading eSIM technology for supporting mobile network operators and global device manufacturers meeting customer demand for eSIM-enabled communications as more devices start shipping without traditional plastic SIMs
  • The unique international capabilities of the core Truphone network and its mobile virtual network operator (MVNO) licenses in nine countries - with new countries to be added - to develop and grow applications in the Internet of Things (IoT) space

Commenting on the acquisition, Pyrros Koussios said: “Truphone is an innovative and highly specialized mobile telecommunications player, with established industry-leading R&D at the forefront of important innovations like the eSIM technology. We were attracted to the breadth and sophistication of the services offered. The company has continued to grow strongly in 2022 despite the uncertainties caused by its prior ownership and delivered growth well above 20%. This impressive performance underlines the quality and resilience of the business as well as the commitment of its employees.”

Hakan Koç added: “I know a great tech company when I see one. Truphone’s R&D hub in Lisbon is impressive. We now look forward to executing on our accelerated growth plans and deliver new and innovative products for our customers. The funding that we are providing will accelerate capital investment in the core network, while building new software and API-driven digital capabilities to address not only the needs of enterprises but also those of tech companies. I consider myself the startup ambassador of the company and it reminds me of banking before the Fintech-wave: this may be one of the last big industries where tech meets legacy processes, and we are here to fix it – it will be fun.”

Jeremy Fletcher, Truphone Chairman said: “We welcome today’s announcement and the certainty that it brings to the business. Koç and Koussios are both successful entrepreneurs, with the right experience, and now that the ownership issue has been resolved, they have a clear plan for growth and building the business for the future. We are delighted that despite the challenges that the company faced, with the help of the Government of the United Kingdom, and, in particular HM Treasury’s OFSI team and the BEIS ISU unit, we have been able to preserve the value of the business and protect the jobs of our employees.”

Harry Odenhoven, CEO at Truphone, added: “Truphone is a great business built on top of a privately owned and operated core global telecommunications network, offering a rich set of value adding communication services to sophisticated multinational clients with international communications needs. We are trusted by leading banks, device manufacturers, network providers and companies around the world– and have played a key role in supporting our partners with the challenges that the current macro-environment continues to bring. I want to thank all our customers and suppliers for the support and trust in the last year and the years to come.”

With coverage in over 200 countries and with over 400 direct network agreements, Truphone offers a rich set of value adding communication services to 2,000+ multinational enterprise customers including most leading global investment banks. Truphone remains committed to delivering communication technology innovations addressing the needs of its demanding global clients.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

FGS Global

R ollo Head
rollo.head@fgsglobal.com
+44 7768 994 987

C arolina Neri
carolina.neri@fgsglobal.com
+44 7502 127 516

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release

Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob

EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release

EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia

Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release

Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye